The company states: "AstraZeneca will present 47 abstracts showcasing new data from across its haematology portfolio and clinical pipeline, demonstrating its commitment to redefining care for hard-to-treat blood diseases at the 64th American Society of Hematology Annual Meeting and Exposition, 10 to 13 December 2022. A total of eight approved and potential new medicines will be featured across more than ten types of blood cancers and rare diseases, including data in chronic lymphocytic leukaemia, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome and amyloid light chain amyloidosis." Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AZN:
- AstraZeneca announces sale of West Chester, Ohio manufacturing site
- National Resilience, AstraZeneca to establish biomanufacturing partnership
- AstraZeneca to acquire Neogene Therapeutics for $320M
- Merck, AstraZeneca announce EMA’s CHMP adopted positive opinion of LYNPARZA
- AstraZeneca Lynparza+biraterone recommended for E.U. approval in mCRPC